The 6-minute walk test as a new outcome measure in duchenne muscular dystrophy

Craig M McDonald; Erik K Henricson; Jay J. Han; R. Ted Abresch; Alina Nicorici; Gary L. Elfring; Leone Atkinson; Allen Reha; Samit Hirawat; Langdon L. Miller

doi:10.1002/mus.21544

The 6-minute walk test as a new outcome measure in duchenne muscular dystrophy

Craig M McDonald, Erik K Henricson, Jay J. Han, R. Ted Abresch, Alina Nicorici, Gary L. Elfring, Leone Atkinson, Allen Reha, Samit Hirawat, Langdon L. Miller

Research output: Contribution to journal › Article › peer-review

231 Scopus citations

Abstract

Walking abnormalities are prominent in Duchenne muscular dystrophy (DMD). We modified the 6-minute walk test (6MWT) for use as an outcome measure in patients with DMD and evaluated its performance in 21 ambulatory boys with DMD and 34 healthy boys, ages 4 to 12 years. Boys with DMD were tested twice, -1 week apart; controls were tested once. The groups had similar age, height, and weight. All tests were completed. Boys who fell recovered rapidly from falls without injury. Mean ± SD [range] 6-minute walk distance (6MWD) was lower in boys with DMD than in controls (366 ± 83 [125-481] m vs. 621 ± 68 [479-754] m; P < 0.0001; unpaired t-test). Test-retest correlation for boys with DMD was high (r = 0.91). Stride length (R² = 0.89; P < 0.0001) was the major determinant of 6MWD for both boys with DMD and controls. A modified 6MWT is feasible and safe, documents disease-related limitations on ambulation, is reproducible, and offers a new outcome measure for DMD natural history and therapeutic trials.

Original language	English (US)
Pages (from-to)	500-510
Number of pages	11
Journal	Muscle and Nerve
Volume	41
Issue number	4
DOIs	https://doi.org/10.1002/mus.21544
State	Published - Apr 2010

Keywords

6-minute walk test
Case-control study
Child
Duchenne
Gait disorder
Muscular dystrophy
Neurologic

ASJC Scopus subject areas

Clinical Neurology
Cellular and Molecular Neuroscience
Physiology (medical)
Physiology

Access to Document

10.1002/mus.21544

Fingerprint Dive into the research topics of 'The 6-minute walk test as a new outcome measure in duchenne muscular dystrophy'. Together they form a unique fingerprint.

Cite this

The 6-minute walk test as a new outcome measure in duchenne muscular dystrophy. / McDonald, Craig M ; Henricson, Erik K; Han, Jay J.; Abresch, R. Ted; Nicorici, Alina; Elfring, Gary L.; Atkinson, Leone; Reha, Allen; Hirawat, Samit; Miller, Langdon L.

In: Muscle and Nerve, Vol. 41, No. 4, 04.2010, p. 500-510.

Research output: Contribution to journal › Article › peer-review

@article{ab2a9d7aea1841afbd6ea9e20be300a0,

title = "The 6-minute walk test as a new outcome measure in duchenne muscular dystrophy",

abstract = "Walking abnormalities are prominent in Duchenne muscular dystrophy (DMD). We modified the 6-minute walk test (6MWT) for use as an outcome measure in patients with DMD and evaluated its performance in 21 ambulatory boys with DMD and 34 healthy boys, ages 4 to 12 years. Boys with DMD were tested twice, -1 week apart; controls were tested once. The groups had similar age, height, and weight. All tests were completed. Boys who fell recovered rapidly from falls without injury. Mean ± SD [range] 6-minute walk distance (6MWD) was lower in boys with DMD than in controls (366 ± 83 [125-481] m vs. 621 ± 68 [479-754] m; P < 0.0001; unpaired t-test). Test-retest correlation for boys with DMD was high (r = 0.91). Stride length (R2 = 0.89; P < 0.0001) was the major determinant of 6MWD for both boys with DMD and controls. A modified 6MWT is feasible and safe, documents disease-related limitations on ambulation, is reproducible, and offers a new outcome measure for DMD natural history and therapeutic trials.",

keywords = "6-minute walk test, Case-control study, Child, Duchenne, Gait disorder, Muscular dystrophy, Neurologic",

author = "McDonald, {Craig M} and Henricson, {Erik K} and Han, {Jay J.} and Abresch, {R. Ted} and Alina Nicorici and Elfring, {Gary L.} and Leone Atkinson and Allen Reha and Samit Hirawat and Miller, {Langdon L.}",

year = "2010",

month = apr,

doi = "10.1002/mus.21544",

language = "English (US)",

volume = "41",

pages = "500--510",

journal = "Muscle and Nerve",

issn = "0148-639X",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - The 6-minute walk test as a new outcome measure in duchenne muscular dystrophy

AU - McDonald, Craig M

AU - Henricson, Erik K

AU - Han, Jay J.

AU - Abresch, R. Ted

AU - Nicorici, Alina

AU - Elfring, Gary L.

AU - Atkinson, Leone

AU - Reha, Allen

AU - Hirawat, Samit

AU - Miller, Langdon L.

PY - 2010/4

Y1 - 2010/4

N2 - Walking abnormalities are prominent in Duchenne muscular dystrophy (DMD). We modified the 6-minute walk test (6MWT) for use as an outcome measure in patients with DMD and evaluated its performance in 21 ambulatory boys with DMD and 34 healthy boys, ages 4 to 12 years. Boys with DMD were tested twice, -1 week apart; controls were tested once. The groups had similar age, height, and weight. All tests were completed. Boys who fell recovered rapidly from falls without injury. Mean ± SD [range] 6-minute walk distance (6MWD) was lower in boys with DMD than in controls (366 ± 83 [125-481] m vs. 621 ± 68 [479-754] m; P < 0.0001; unpaired t-test). Test-retest correlation for boys with DMD was high (r = 0.91). Stride length (R2 = 0.89; P < 0.0001) was the major determinant of 6MWD for both boys with DMD and controls. A modified 6MWT is feasible and safe, documents disease-related limitations on ambulation, is reproducible, and offers a new outcome measure for DMD natural history and therapeutic trials.

AB - Walking abnormalities are prominent in Duchenne muscular dystrophy (DMD). We modified the 6-minute walk test (6MWT) for use as an outcome measure in patients with DMD and evaluated its performance in 21 ambulatory boys with DMD and 34 healthy boys, ages 4 to 12 years. Boys with DMD were tested twice, -1 week apart; controls were tested once. The groups had similar age, height, and weight. All tests were completed. Boys who fell recovered rapidly from falls without injury. Mean ± SD [range] 6-minute walk distance (6MWD) was lower in boys with DMD than in controls (366 ± 83 [125-481] m vs. 621 ± 68 [479-754] m; P < 0.0001; unpaired t-test). Test-retest correlation for boys with DMD was high (r = 0.91). Stride length (R2 = 0.89; P < 0.0001) was the major determinant of 6MWD for both boys with DMD and controls. A modified 6MWT is feasible and safe, documents disease-related limitations on ambulation, is reproducible, and offers a new outcome measure for DMD natural history and therapeutic trials.

KW - 6-minute walk test

KW - Case-control study

KW - Child

KW - Duchenne

KW - Gait disorder

KW - Muscular dystrophy

KW - Neurologic

UR - http://www.scopus.com/inward/record.url?scp=77950210043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950210043&partnerID=8YFLogxK

U2 - 10.1002/mus.21544

DO - 10.1002/mus.21544

M3 - Article

C2 - 19941337

AN - SCOPUS:77950210043

VL - 41

SP - 500

EP - 510

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 4

ER -

The 6-minute walk test as a new outcome measure in duchenne muscular dystrophy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this